Martin Wernli

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Daniel Betticher, Shu‐Fang Hsu Schmitz, Martin Tötsch et al. · Journal of Clinical Oncology · 2003 · 455 citations

Medicine, Oncology, Pharmacology +17

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

Arnaud Roth, Nicola Fazio, Roger Stupp et al. · Journal of Clinical Oncology · 2007 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

Daniel Betticher, S-F Hsu Schmitz, Martin Tötsch et al. · British Journal of Cancer · 2006 · 208 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Susanne Saußele, Marie-Paloma Krauß, Rüdiger Hehlmann et al. · Blood · 2015 · 200 citations · Full text

Medicine, Hematology, Oncology +12